 |
 |
|
|
|
| Lyrica |
 |
| C8H17NO2 |
 |
| 148553-50-8 |
 |
Pregabalin powder is a gabapentin-class medication that works by inhibiting specific calcium channels. Pregabalin
powder was initially designed to treat epilepsy because its mechanism of action is similar to that of gabapentin, which can prevent seizures by modulating voltage-dependent calcium channels in the central nervous system.In clinical trials, however, researchers discovered that it is also quite efficient in pain management. Pregabalin powder reduces neuropathic pain, diabetic peripheral neuropathy, and other symptoms by boosting
GABA
levels in the body and suppressing the release of excitatory neurotransmitters. Pregabalin powder can also be used to treat a number of pain conditions, including fibromyalgia and postherpetic neuralgia. As a result, pregabalin powder is widely utilized in the treatment of various forms of pain and has emerged as a key medicine in the clinical treatment of neuropathic pain.
Benefits of Using Pregabalin Powder
1.Diabetic Peripheral Neuropathy (DPN)
Diabetic peripheral neuropathy (DPN) is a common consequence of both type 1 and type 2 diabetes, affecting around 30-40% of diabetics. Symptoms of this nerve condition in the hands and feet include pain, weakness, and loss of sensation. Pregabalin powder is the first-line medication for DPN, offering significant pain relief while also addressing comorbidities like anxiety and insomnia. More research is needed, however, to completely understand pregabalin is therapeutic effects on anxiety and sleep disorders, as well as to discover which individuals would benefit the most from this medication.
2.Postherpetic Neuralgia (PHN)
Postherpetic neuralgia (PHN) is a debilitating chronic pain syndrome that can develop after a herpes zoster epidemic and becomes more common as patients age. PHN can be difficult to treat and frequently necessitates the use of multiple medicines in order to get meaningful pain reduction. Pregabalin powder is the most recent drug to be approved for PHN. Data demonstrate efficacy for pain alleviation and sleep disruption caused by PHN in affected patients. Although there have been no direct comparisons, pregabalin looks to be equivalent to gabapentin and other first-line medications for the treatment of PHN.
3.Partial Epilepsy
Pregabalin powder
has been licensed and marketed antiepileptic drug for use as adjunctive treatment of partial epilepsy. It acts at presynaptic calcium channels, modulating neurotransmitter release in the CNS.
Three multi-centre randomised, double-blind, placebo-controlled trials enrolling patients with refractory partial epilepsy have demonstrated an antiepileptic effect of pregabalin against placebo, as adjunctive therapy, with 31–
51% of patients showing a 50% reduction in seizure frequency.
4.Fibromyalgia
Pregabalin powder is expected to alleviate fibromyalgia pain by limiting sensory propagation of nociception via calcium channel blockage and neurotransmitter release in the ascending pain pathway. Pregabalin has also been demonstrated to lower glutamate and glutamine levels in the posterior insula of fibromyalgia patients, interfering with its functional connection to the default mode network.
Occipital nerve stimulation (ONS) studies on fibromyalgia patients demonstrate impaired conditioned pain modulation. Pregabalin has been demonstrated to have impacts on descending pain circuitry in nerve-injured rats
thus, pregabalin is central effects may contribute to its efficacy in treating fibromyalgia.
5.Neuropathic Pain
Pregabalin powder is a voltage-gated Ca2+ channel antagonist that binds exclusively to the alpha-2-delta subunit to generate analgesic effects. It effectively cures the symptoms of numerous types of neuropathic pain and has evolved into a first-line therapy medicine with high safety and efficacy. It has been proven in preclinical research in numerous animal models of neuropathic pain to be useful in the treatment of symptoms such as allodynia and hyperalgesia.
6.Generalized Anxiety Disorder (GAD)
Studies have shown that pregabalin is consistently efficient in treating generalized anxiety disorder (GAD). In a critical review, seven out of eight randomized and controlled trials reported statistically significant reductions in Hamilton Anxiety Rating Scale scores with pregabalin powder doses ranging from 150-600 mg. In a separate study involving GAD patients who received pregabalin powder treatment for 12-24 weeks, the incidence of withdrawal symptoms and rebound anxiety after discontinuation was low. Pregabalin powder can also be an effective treatment option for patients with GAD who have not responded well to antidepressant therapy.
|
 |
medical use
|
 |
Molecular Weight:159.23
Melt Point:194-196¡ÆC
Color:White or off white crystal powde
solubility £ºdeionized water: ¡Ã10mg/mL |
| Industrial field |
pharmaceutical |
|
|
 |
 |
|
AASraw/Aea.ltd
|
| Phone |
+13204026693 |
| Fax |
|
| Homepage |
- |
| E-mail |
King@aea.ltd
|
| Address |
FLAT/RM C1 4/F SUMMIT BUILDING 30 MAN YUE STREET HUNG HOM,HONG KONG,CHINA |
|
 |
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
|
|
|
|
